18F-Flurpiridaz PET与SPECT心肌灌注显像在小左心室患者中的诊断效能比较:III期临床试验亚组分析
该研究为18F-flurpiridaz III期临床试验的亚组分析(n=750),按左心室舒张末期容积中位数113 mL将患者分为小左心室(n=369)和大左心室(n=381),比较99mTc-SPECT与18F-flurpiridaz PET心肌灌注显像的诊断效能,以定量有创冠状动脉造影为参考标准。结果显示SPECT的AUC在小左心室中显著下降(0.75 vs. 0.67,P=0.03),而PET不受左心室大小影响(AUC 0.79 vs. 0.77,P=0.49),小左心室中PET的AUC显著高于SPECT(0.77 vs. 0.67,P<0.0001)。
要点
- SPECT诊断效能随左心室变小而下降,PET不受左心室大小影响。
- 小左心室中PET的AUC显著高于SPECT(0.77 vs. 0.67)。
- 小左心室中PET灵敏度显著高于SPECT(67% vs. 43%)。
核心结论
- 18F-flurpiridaz PET心肌灌注显像的诊断效能不受左心室大小影响,且在小左心室患者中优于SPECT。
研究设计与样本
- 18F-flurpiridaz III期临床试验(n=750)的亚组分析,按PET左心室舒张末期容积中位数113 mL分层:小左心室(<113 mL,n=369)和大左心室(≥113 mL,n=381)。
- 图像由3名独立设盲读者按多数原则判读,参考标准为定量有创冠状动脉造影,至少1支冠状动脉狭窄≥50%定义为显著。
主要发现
- SPECT的AUC从大左心室的0.75显著降至小左心室的0.67(P=0.03),而PET在大左心室与小左心室的AUC相似(0.79 vs. 0.77,P=0.49)。
- 小左心室中PET的AUC(0.77)显著高于SPECT(0.67)(P<0.0001),该现象由女性患者驱动(P<0.0001)。
- 小左心室中SPECT灵敏度显著下降(P<0.001),而PET灵敏度随左心室大小无显著变化(P=0.07)。
- PET灵敏度在小左心室(67% vs. 43%,P<0.001)和大左心室(76% vs. 61%,P<0.001)均显著高于SPECT。
- 大左心室中PET与SPECT特异度相似(76% vs. 83%,P=0.11);SPECT特异度在小左心室较大左心室改善(90% vs. 83%,P=0.03),PET特异度不随左心室大小变化(76% vs. 76%,P=0.9)。
临床怎么用
- 对于左心室较小的患者(尤其是女性),选择18F-flurpiridaz PET心肌灌注显像可能获得优于SPECT的诊断效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The performance of SPECT myocardial perfusion imaging (MPI) may deteriorate in smaller hearts, primarily because of the lower resolution of conventional Anger cameras. 18F-flurpiridaz is a novel PET MPI agent with superior image and defect resolution. We sought to determine the diagnostic performance of 99mTc-labeled SPECT MPI compared with 18F-flurpiridaz PET MPI according to left ventricle (LV) size. Methods: We conducted a substudy of the phase III clinical trial of flurpiridaz (n = 750) and stratified diagnostic performance according to the median PET LV end-diastolic volume (LVEDV), with smaller LVs defined as having an LVEDV of less than 113 mL (n = 369) and larger LVs defined as having an LVEDV of at least 113 mL (n = 381). Images were interpreted by the majority rule of 3 independent masked readers. The reference standard was quantitative invasive angiography, with at least 50% stenosis in at least 1 coronary artery considered significant. Results: SPECT performance decreased significantly from an area under the curve (AUC) of 0.75 in larger LVs to 0.67 in smaller LVs (P = 0.03), whereas PET performance was similar in larger and smaller LVs (AUC, 0.79 vs. 0.77, P = 0.49). Accordingly, in smaller LVs, PET had a higher AUC (0.77) than the SPECT AUC (0.67) (P < 0.0001), a phenomenon driven by female patients (P < 0.0001). In smaller LVs, there was a degradation of SPECT sensitivity that was highly significant (P < 0.001), whereas there was no significant change in PET sensitivity according to LV size (P = 0.07). Overall, PET had significantly higher sensitivity than SPECT in both smaller LVs (67% vs. 43%, P < 0.001) and larger LVs (76% vs. 61%, P < 0.001). The specificities of PET and SPECT were similar in larger LVs (76% vs. 83%, P = 0.11). Although SPECT specificity improved in smaller compared with larger LVs (90% vs. 83%, P = 0.03), the PET specificity did not change with LV size (76% vs. 76%, P = 0.9). Conclusion: The diagnostic performance of 18F-flurpiridaz PET MPI is not affected by LV size and is superior to SPECT MPI in patients with smaller LVs, highlighting the importance of appropriate test selection in these patients.
引用
- Packard RRS, Lazewatsky JL, Orlandi C, et al. Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of the 18F-Flurpiridaz Phase III Clinical Trial. J Nucl Med. 2020. PMID: 33246979. doi:10.2967/jnumed.120.252007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。